Accepted at 2:16 a.m. Nov, 01, 2023 by dollajas
Author: AbdelrahmanMahmoud
Co-authors: dollajas
Related Note: 1509140057996 1
Rationale for change

both amboss and bnb (The combination of methotrexate (IM or oral) and misoprostol (oral or vaginal) is no longer recommended in the US as standard of care.) [https://next.amboss.com/us/article/jG0__h] Procedure/application >> first trimester

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy


Watch Methotrexate, Leucovorin, 5-fluorouracil, Hydroxyurea
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo

Bootcamp
Watch associated Bootcamp video - Clinical Applications of the Pyrimidine Pathway

Watch associated Bootcamp video - Mucosal Barrier Protectants
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::12_Antimetabolites::Pyrimidine_Synthesis_Inhibitors::Methotrexate #AK_Step1_v12::#B&B::20_Repro::02_Pregnancy::04_Pregnancy #AK_Step1_v12::#AMBOSS::QZauYQ #AK_Step2_v12::#AMBOSS::86aO5l #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_leucovorin,_5-fluorouracil,_hydroxyurea #AK_Step1_v12::#OME::PreClinical::Gastrointestinal #AK_Step1_v12::#B&B::11_Hematology::04_Cancer_Drugs::01_Antimetabolites #AK_Step1_v12::#Bootcamp::Gastroenterology::10_Pharmacology::08_Mucosal_Barrier_Protectants #AK_Step1_v12::#Physeo::09_Pharm::11_Gastrointestinal::05_Misoprostol !AK_UpdateTags::Step1decks::Lolnotacop::Drugs #AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::10_5-FU_Methotrexate_Leucovorin_Hydroxyurea #AK_Step1_v12::#AMBOSS::86aO5l #AK_Step3_v12::#UWorld::112586 #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::12_Antimetabolites